PulpitisPhase 3NCT07919938
Submucosal Cryotherapy and Anti-inflammatory Drugs for Postoperative Pain Following Root Canal Treatment in Maxillary Molars
A Phase 3 study testing Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy and Diclofenac Sodium in people with Pulpitis, run by Suez Canal University at 1 site in Egypt.
Trial summary
Pain after root canal treatment is a common problem, particularly in teeth with symptomatic irreversible pulpitis, a condition involving severe inflammation of the tissue inside the tooth. Read more about this study
- Who is it for?
- Ages 21 to 50 years
- Conditions the study is for
- Pulpitis
- What is being tested?
- Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy and Diclofenac Sodium
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Nov 2026to 15 Nov 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adult patients aged 21-50 years.
- Maxillary first or second molars diagnosed with symptomatic irreversible pulpitis.
- Teeth with mature roots and normal apical tissues or without radiographic evidence of apical pathosis.
- Vital teeth exhibiting an exaggerated and lingering response to thermal stimuli.
- Patients experiencing moderate to severe preoperative pain.
- Patients classified as American Society of Anesthesiologists (ASA) physical status I or II.
- Teeth considered restorable and suitable for rubber dam isolation.
Who cannot join
- Patients with known hypersensitivity or allergy to articaine, diclofenac sodium, dexamethasone, or any materials used in the study.
- Patients who have received analgesics, anti-inflammatory drugs, corticosteroids, or antibiotics within the preceding 48-72 hours.
- Pregnant or lactating women.
- Medically compromised patients or those receiving immunosuppressive therapy.
- Teeth with periapical lesions, swelling, sinus tracts, tenderness to percussion, or symptomatic apical periodontitis.
- Previously initiated or previously treated teeth.
- Teeth with periodontal pockets, root resorption, calcified canals, or non-restorable coronal structures.
- Cases involving procedural complications, including perforation, instrument separation, or inability to complete root canal treatment according to the standardized protocol.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site
Endodontics Department, Faculty of Dentistry, Suez Canal University
Ismailia, Ismailia Governorate, 41522
Hisham E El- Sayed, MSc, 0 10 92192763 ext. +2, hesham_elsayed@dent.suez.edu.eg
About this study
Official title: Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study
Pain after root canal treatment is a common problem, particularly in teeth with symptomatic irreversible pulpitis, a condition involving severe inflammation of the tissue inside the tooth. Submucosal cryotherapy, which involves applying cold saline through an injection near the affected tooth, may help reduce postoperative pain and inflammation. Anti-inflammatory medications, such as diclofenac sodium and dexamethasone, may also provide pain relief.
This randomized clinical trial aims to evaluate the effects of submucosal cryotherapy, alone or combined with anti-inflammatory medications, on postoperative pain and interleukin-6 (IL-6) levels in patients undergoing root canal treatment of upper molars with symptomatic irreversible pulpitis.
Read more
A total of 90 adult patients will be randomly assigned to six groups: local anesthesia alone, cryotherapy with anesthesia, diclofenac sodium with anesthesia, dexamethasone with anesthesia, cryotherapy combined with diclofenac sodium, or cryotherapy combined with dexamethasone. All participants will undergo standardized single-visit root canal treatment.
Postoperative pain will be evaluated during the first 72 hours after treatment. IL-6, a substance involved in inflammation, will be measured in blood samples collected from the dental pulp during treatment. The need for additional pain medication and the occurrence of postoperative flare-ups will also be assessed.
The study seeks to determine whether combining submucosal cryotherapy with anti-inflammatory medications provides greater postoperative pain relief than individual interventions or standard care alone.
- Conditions
- Pulpitis
- Being tested
- Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy, Diclofenac Sodium, Dexamethasone Sodium Phosphate
- Keywords
- Symptomatic Irreversible Pulpitis, Submucosal Cryotherapy, Root Canal Treatment, Endodontic Pain, Diclofenac Sodium, Dexamethasone Sodium Phosphate, Interleukin-6, Postoperative Pain Management
- Medical subject headings
- Pulpitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Articaine Hydrochloride With EpinephrineDrug
Local anesthesia will be administered using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 by buccal infiltration before single-visit root canal treatment. Supplemental palatal infiltration will be provided if needed, and any additional anesthetic administration will be recorded. This standard anesthetic regimen will be used in all six study groups.
Submucosal CryotherapyProcedure or surgery
Submucosal cryotherapy will be performed through a single injection of 1 mL sterile normal saline cooled to 2-5°C into the buccal vestibule adjacent to the affected maxillary molar before root canal treatment. The intervention is intended to provide localized cooling to reduce postoperative inflammation and pain. Cryotherapy will be administered alone or in combination with an anti-inflammatory drug according to group allocation.
Diclofenac SodiumDrug
Diclofenac sodium will be administered as a single preoperative submucosal injection of 1 mL at a concentration of 25 mg/mL (total dose: 25 mg) into the buccal vestibule adjacent to the affected maxillary molar. It will be administered alone or in combination with submucosal cryotherapy according to group allocation to evaluate its effects on postoperative pain and inflammatory response.
Dexamethasone Sodium PhosphateDrug
Dexamethasone sodium phosphate will be administered as a single preoperative submucosal injection of 1 mL at a concentration of 4 mg/mL (total dose: 4 mg) into the buccal vestibule adjacent to the affected maxillary molar. It will be administered alone or in combination with submucosal cryotherapy according to group allocation to evaluate its effects on postoperative pain and inflammatory response.
| Study group | Role | What they receive |
|---|---|---|
| Anesthesia Alone (Control Group) | Active comparator | Participants will receive local anesthesia using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 administered by buccal infiltration, with supplemental palatal infiltration if needed. Standardized single-visit root canal treatment will be performed without additional submucosal cryotherapy or anti-inflammatory drug injections. Receives: Drug: Articaine Hydrochloride With Epinephrine |
| Submucosal Cryotherapy With Anesthesia | Experimental | Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL cold normal saline (2-5°C) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. Receives: Drug: Articaine Hydrochloride With Epinephrine; Procedure: Submucosal Cryotherapy |
| Diclofenac Sodium With Anesthesia | Experimental | Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL diclofenac sodium (25 mg/mL; total dose 25 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. Receives: Drug: Articaine Hydrochloride With Epinephrine; Drug: Diclofenac Sodium |
| Dexamethasone With Anesthesia | Experimental | Participants will receive standard local anesthesia followed by a single submucosal injection of 1 mL dexamethasone sodium phosphate (4 mg/mL; total dose 4 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. Receives: Drug: Articaine Hydrochloride With Epinephrine; Drug: Dexamethasone Sodium Phosphate |
| Submucosal Cryotherapy With Diclofenac Sodium | Experimental | Participants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and diclofenac sodium (1 mL at 25 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol. Receives: Drug: Articaine Hydrochloride With Epinephrine; Procedure: Submucosal Cryotherapy; Drug: Diclofenac Sodium |
| Submucosal Cryotherapy With Dexamethasone | Experimental | Participants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and dexamethasone sodium phosphate (1 mL at 4 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol. Receives: Drug: Articaine Hydrochloride With Epinephrine; Procedure: Submucosal Cryotherapy; Drug: Dexamethasone Sodium Phosphate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS)
Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Participants will record their pain intensity at predefined postoperative intervals, and NRS scores will be compared among the six study groups.
Measured: At 6, 12, 24, 48, and 72 hours after root canal treatment.
Secondary outcomes (3)
Interleukin-6 (IL-6) Levels in Pulpal Blood
Interleukin-6 (IL-6) levels will be measured in pulpal blood samples collected under aseptic conditions after access cavity opening during root canal treatment. Samples will be stored at -20°C and analyzed using enzyme-linked immunosorbent assay (ELISA). IL-6 levels will be compared among the six study groups to evaluate the local inflammatory response.
Measured: During root canal treatment, immediately after access cavity opening (single intraoperative sample).
Incidence of Postoperative Flare-Up
The occurrence of postoperative flare-up following single-visit root canal treatment will be recorded. The number and percentage of participants experiencing flare-up will be determined and compared among the six study groups.
Measured: Within 72 hours after root canal treatment.
Incidence of Postoperative Rescue Analgesic Intake
Participants will be instructed to avoid taking analgesics unless necessary. Any postoperative rescue analgesic intake will be recorded. The number and percentage of participants requiring rescue analgesics will be compared among the six study groups.
Measured: Within 72 hours after root canal treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start15 Nov 2026 (estimated)
- Primary completion15 Nov 2027 (estimated)
- Study completion15 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PulpitisStudies of the same condition, open and under way.
- More trials run by Suez Canal UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This prospective, randomized, parallel-group clinical trial will include 90 patients with symptomatic irreversible pulpitis in maxillary molars. Participants will be randomly allocated in a 1:1:1:1:1:1 ratio to six groups (15 patients per group): anesthesia alone, anesthesia with submucosal cryotherapy, anesthesia with diclofenac sodium, anesthesia with dexamethasone, anesthesia with cryotherapy and diclofenac sodium, or anesthesia with cryotherapy and dexamethasone. All participants will undergo standardized single-visit root canal treatment.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Suez Canal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, hisham elsayed, Suez Canal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07919938
- Sponsor's protocol ID
- 1160/2026
- Status last verified
- Oct 2026
- First submitted
- 31 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Submucosal Cryotherapy With or Without Different Anti-inflammatory Drugs on Postoperative Pain and Interleukin-6 Levels in Maxillary Molars With Symptomatic Irreversible Pulpitis: A Randomized Clinical Study
- ClinicalTrials.gov ID
- NCT07919938
- Acronym / sponsor ID
- 1160/2026
- Conditions
- Pulpitis
- Keywords
- Symptomatic Irreversible Pulpitis, Submucosal Cryotherapy, Root Canal Treatment, Endodontic Pain, Diclofenac Sodium, Dexamethasone Sodium Phosphate, Interleukin-6, Postoperative Pain Management
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Suez Canal UniversityUniversity, hospital or other
- Study start
- 15 Nov 2026 (estimated)
- Primary completion
- 15 Nov 2027 (estimated)
- Study completion
- 15 Nov 2027 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pain after root canal treatment is a common problem, particularly in teeth with symptomatic irreversible pulpitis, a condition involving severe inflammation of the tissue inside the tooth. Submucosal cryotherapy, which involves applying cold saline through an injection near the affected tooth, may help reduce postoperative pain and inflammation. Anti-inflammatory medications, such as diclofenac sodium and dexamethasone, may also provide pain relief.
This randomized clinical trial aims to evaluate the effects of submucosal cryotherapy, alone or combined with anti-inflammatory medications, on postoperative pain and interleukin-6 (IL-6) levels in patients undergoing root canal treatment of upper molars with symptomatic irreversible pulpitis.
A total of 90 adult patients will be randomly assigned to six groups: local anesthesia alone, cryotherapy with anesthesia, diclofenac sodium with anesthesia, dexamethasone with anesthesia, cryotherapy combined with diclofenac sodium, or cryotherapy combined with dexamethasone. All participants will undergo standardized single-visit root canal treatment.
Postoperative pain will be evaluated during the first 72 hours after treatment. IL-6, a substance involved in inflammation, will be measured in blood samples collected from the dental pulp during treatment. The need for additional pain medication and the occurrence of postoperative flare-ups will also be assessed.
The study seeks to determine whether combining submucosal cryotherapy with anti-inflammatory medications provides greater postoperative pain relief than individual interventions or standard care alone.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 6
- Model description
- This prospective, randomized, parallel-group clinical trial will include 90 patients with symptomatic irreversible pulpitis in maxillary molars. Participants will be randomly allocated in a 1:1:1:1:1:1 ratio to six groups (15 patients per group): anesthesia alone, anesthesia with submucosal cryotherapy, anesthesia with diclofenac sodium, anesthesia with dexamethasone, anesthesia with cryotherapy and diclofenac sodium, or anesthesia with cryotherapy and dexamethasone. All participants will undergo standardized single-visit root canal treatment.
| Arm | Type | Receives |
|---|---|---|
| Anesthesia Alone (Control Group) | Active comparator | Drug: Articaine Hydrochloride With EpinephrineParticipants will receive local anesthesia using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 administered by buccal infiltration, with supplemental palatal infiltration if needed. Standardized single-visit root canal treatment will be performed without additional submucosal cryotherapy or anti-inflammatory drug injections. |
| Submucosal Cryotherapy With Anesthesia | Experimental | Drug: Articaine Hydrochloride With Epinephrine, Procedure: Submucosal CryotherapyParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL cold normal saline (2-5°C) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. |
| Diclofenac Sodium With Anesthesia | Experimental | Drug: Articaine Hydrochloride With Epinephrine, Drug: Diclofenac SodiumParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL diclofenac sodium (25 mg/mL; total dose 25 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. |
| Dexamethasone With Anesthesia | Experimental | Drug: Articaine Hydrochloride With Epinephrine, Drug: Dexamethasone Sodium PhosphateParticipants will receive standard local anesthesia followed by a single submucosal injection of 1 mL dexamethasone sodium phosphate (4 mg/mL; total dose 4 mg) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. |
| Submucosal Cryotherapy With Diclofenac Sodium | Experimental | Drug: Articaine Hydrochloride With Epinephrine, Procedure: Submucosal Cryotherapy, Drug: Diclofenac SodiumParticipants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and diclofenac sodium (1 mL at 25 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol. |
| Submucosal Cryotherapy With Dexamethasone | Experimental | Drug: Articaine Hydrochloride With Epinephrine, Procedure: Submucosal Cryotherapy, Drug: Dexamethasone Sodium PhosphateParticipants will receive standard local anesthesia followed by submucosal administration of cold normal saline (1 mL at 2-5°C) and dexamethasone sodium phosphate (1 mL at 4 mg/mL) into the buccal vestibule adjacent to the affected maxillary molar before standardized single-visit root canal treatment. The interventions will be administered separately or sequentially according to the finalized study protocol. |
Who may qualify
- Ages
- 21 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Adult patients aged 21-50 years.
- Maxillary first or second molars diagnosed with symptomatic irreversible pulpitis.
- Teeth with mature roots and normal apical tissues or without radiographic evidence of apical pathosis.
- Vital teeth exhibiting an exaggerated and lingering response to thermal stimuli.
- Patients experiencing moderate to severe preoperative pain.
Key exclusion criteria (8 listed)
- Patients with known hypersensitivity or allergy to articaine, diclofenac sodium, dexamethasone, or any materials used in the study.
- Patients who have received analgesics, anti-inflammatory drugs, corticosteroids, or antibiotics within the preceding 48-72 hours.
- Pregnant or lactating women.
- Medically compromised patients or those receiving immunosuppressive therapy.
- Teeth with periapical lesions, swelling, sinus tracts, tenderness to percussion, or symptomatic apical periodontitis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Articaine Hydrochloride With EpinephrineLocal anesthesia will be administered using one carpule of 4% articaine hydrochloride with epinephrine 1:100,000 by buccal infiltration before single-visit root canal treatment. Supplemental palatal infiltration will be provided if needed, and any additional anesthetic administration will be recorded. This standard anesthetic regimen will be used in all six study groups. | Drug | Anesthesia Alone (Control Group), Dexamethasone With Anesthesia, Diclofenac Sodium With Anesthesia, Submucosal Cryotherapy With Anesthesia, Submucosal Cryotherapy With Dexamethasone, Submucosal Cryotherapy With Diclofenac Sodium |
| Submucosal CryotherapySubmucosal cryotherapy will be performed through a single injection of 1 mL sterile normal saline cooled to 2-5°C into the buccal vestibule adjacent to the affected maxillary molar before root canal treatment. The intervention is intended to provide localized cooling to reduce postoperative inflammation and pain. Cryotherapy will be administered alone or in combination with an anti-inflammatory drug according to group allocation. | Procedure or surgery | Submucosal Cryotherapy With Anesthesia, Submucosal Cryotherapy With Dexamethasone, Submucosal Cryotherapy With Diclofenac Sodium |
| Diclofenac SodiumDiclofenac sodium will be administered as a single preoperative submucosal injection of 1 mL at a concentration of 25 mg/mL (total dose: 25 mg) into the buccal vestibule adjacent to the affected maxillary molar. It will be administered alone or in combination with submucosal cryotherapy according to group allocation to evaluate its effects on postoperative pain and inflammatory response. | Drug | Diclofenac Sodium With Anesthesia, Submucosal Cryotherapy With Diclofenac Sodium |
| Dexamethasone Sodium PhosphateDexamethasone sodium phosphate will be administered as a single preoperative submucosal injection of 1 mL at a concentration of 4 mg/mL (total dose: 4 mg) into the buccal vestibule adjacent to the affected maxillary molar. It will be administered alone or in combination with submucosal cryotherapy according to group allocation to evaluate its effects on postoperative pain and inflammatory response. | Drug | Dexamethasone With Anesthesia, Submucosal Cryotherapy With Dexamethasone |
Primary outcome
Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS)
Time frame: At 6, 12, 24, 48, and 72 hours after root canal treatment.
Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Participants will record their pain intensity at predefined postoperative intervals, and NRS scores will be compared among the six study groups.
3 secondary outcomes
Interleukin-6 (IL-6) Levels in Pulpal Blood
Time frame: During root canal treatment, immediately after access cavity opening (single intraoperative sample).
Incidence of Postoperative Flare-Up
Time frame: Within 72 hours after root canal treatment.
Incidence of Postoperative Rescue Analgesic Intake
Time frame: Within 72 hours after root canal treatment.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Related trials for Pulpitis
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Recruiting
Intraligamentary vs Inferior Alveolar Nerve Block for Pulpitis: A Randomized Clinical Trial
Symptomatic Irreversible Pulpitis (SIP), Dental Pain
Not yet recruitingPhase 4
Cost-Effectiveness of Upfront Supplemental Anaesthesia in Symptomatic Irreversible Pulpitis
Irreversible Pulpitis, Anesthesia, Local
Recruiting
Effect of Menstrual Phase on the Anesthetic Efficacy
Pulpitis - Irreversible
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Articaine Hydrochloride With Epinephrine, Submucosal Cryotherapy and Diclofenac Sodium in people with Pulpitis, run by Suez Canal University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hisham E El- Sayed, MSc (0 10 92192763 ext. +2, hesham_elsayed@dent.suez.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain Intensity Assessed Using the Numeric Rating Scale (NRS) (time frame: At 6, 12, 24, 48, and 72 hours after root canal treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.